BUSINESS4 years ago
InMed Pharmaceuticals Inc (NASDAQ:INM) Reports Tolerability And Strong Safety Data For INM-755 In Q2 2021
InMed Pharmaceuticals Inc (NASDAQ:INM) achieved several risk-mitigating and value-adding milestones in IntegraSyn production approach and therapeutic programs. Eric A. Adams, CEO of InMed, said the company...